Communiqués Verastem, Inc.

Actions

VSTM

US92337C2035

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 19:03:44 23/07/2026			Varia. 5j.	Varia. 1 janv.
6,235 ^USD	+5,86%		+7,97%	-19,30%

07/07	VERASTEM, INC. : RBC Capital Markets toujours à l'achat	ZM
24/06	La mise à jour de Verastem sur le VS-7375 réaffirme son potentiel chez les patients américains, selon RBC	MT

Communiqués

13:30	Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026	BU
22/07	Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer	BU
02/07	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
23/06	VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors	BU
17/06	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer	BU
16/06	Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer	BU
15/06	Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program	BU
03/06	Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	BU
27/05	Verastem Oncology to Present at Jefferies Healthcare Conference	BU
26/05	Verastem Oncology Appoints Michael P. Bailey to its Board of Directors	BU
12/05	Verastem Oncology to Present at Upcoming Investor Conferences	BU
11/05	On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer	AQ
08/05	On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer	BU
08/05	Verastem : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Verastem: Q1 Earnings Snapshot	AQ
07/05	Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates	BU
30/04	Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer	BU
23/04	Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026	BU
13/04	Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers	AQ
10/04	Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers	BU
02/04	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
18/03	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules	AQ
17/03	Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026	BU
17/03	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers	BU
04/03	Verastem: Q4 Earnings Snapshot	AQ